The public issue is entirely an offer-for-sale (OFS) of up to 21.7 million shares by the promoters and other shareholders to the tune of around ₹1,800 crore, said bankers. The company operates under the “Blue Jet” brand offering niche products targeted at innovator pharmaceutical companies and multinational generic pharmaceutical companies.
Ahead of Market: 10 things that will decide stock market action on Monday
Sensex and Nifty ended last week lower amid range-bound trading, with broader markets also under pressure. Analysts identified four key factors that could drive Dalal